Department of Medicine, University of Chicago, IL 60637, USA.
Pharmacogenomics. 2010 Apr;11(4):471-4. doi: 10.2217/pgs.10.11.
Pharmacogenomics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents. Both candidate gene and genome-wide approaches have been used to identify genetic markers associated with chemotherapeutic response and/or toxicity. New molecular targeted agents have been designed based on a sophisticated understanding of the molecular alterations defining cancers. Over the next decade, the translation of these findings into clinical practice, as well as functional studies of genetic variants, is likely to take center stage. More comprehensive evaluation of the human genome, including the examination of rare SNPs, copy number variations, tandem repeats and epigenetic effects, will further improve our understanding of the relationship between genetics and drug response.
药物基因组学正在成为新药开发和提高现有化疗药物疗效的重要组成部分。候选基因和全基因组方法都被用于识别与化疗反应和/或毒性相关的遗传标记。新的分子靶向药物是基于对定义癌症的分子改变的深入了解而设计的。在未来十年，这些发现转化为临床实践，以及对遗传变异的功能研究，可能将成为关注的焦点。更全面地评估人类基因组，包括检查罕见的单核苷酸多态性、拷贝数变异、串联重复和表观遗传效应，将进一步提高我们对遗传与药物反应之间关系的理解。
